Strand Life Sciences, a cutting-edge biotechnology company, is at the forefront of transforming genetic diagnostics in India.
Founded in 2000 by Ramesh Hariharan, Vijay Chandru, Swami Manohar, and Vinay V, Strand Life Sciences has grown from a spin-off of the prestigious Indian Institute of Science into a leader in the field of genomics, offering innovative solutions to complex genetic challenges.
Addressing a Critical Need
Strand Life Sciences is tackling a crucial issue in the realm of healthcare: the need for accurate, accessible, and culturally relevant genomic diagnostics.
With the rise of genetic disorders and the increasing demand for personalized medicine, the company has focused on developing tests that cater specifically to Indian genetic profiles and conditions.
The company’s latest breakthrough is the Non-Invasive Prenatal Screening (NIPS), designed to detect potential genetic disorders in fetuses with unprecedented precision.
This test, validated on Indian samples and conditions, marks a significant advancement in prenatal care, allowing expectant parents to make informed decisions with greater confidence.
A Legacy of Innovation
With over 20 years of experience, Strand Life Sciences has made remarkable strides in genomic research and technology.
The company established India’s first College of American Pathologists-accredited laboratory for genomic sequencing and has contributed to approximately 25,000 peer-reviewed scientific publications.
Their expertise spans across various aspects of genomics, including oncology, rare diseases, reproductive health, and general wellness.
Strand Life Sciences has developed a comprehensive range of tests, including the Breast Assure test for hereditary breast and ovarian cancer syndrome (HBOC) and extensive gene panels for cancer risk assessment.
Their Exome and Low Pass Whole Genome tests cover around 5,000 Mendelian disorders, offering industry-leading diagnostic accuracy.
Advanced Technology and Robust Platforms
Central to Strand Life Sciences’ success is their investment in advanced bioinformatics platforms.
Their proprietary tools, Strand NGS, Strand Omics, and Strand Iris, are designed to handle massive datasets, identify key genomic variants, and guide treatment decisions.
These platforms have been validated through extensive use and have been instrumental in the company’s high diagnostic accuracy.
Strand’s commitment to excellence is also evident in their COVID-19 genomic surveillance efforts.
As part of the INSACOG consortium, the company has played a crucial role in monitoring SARS-CoV-2 strains in India, contributing to public health strategies during the pandemic.
A Vision for the Future
Strand Life Sciences is driven by a mission to make genomic sequencing accessible to everyone.
Their goal is to reduce the burden of genetic diseases through early detection and preventive care.
By leveraging their expertise and state-of-the-art technology, the company aims to revolutionize how genetic information is utilized to improve health outcomes.
The company’s partnership with Reliance, one of India’s leading corporate groups, further bolsters its mission.
With strategic support and investment from Reliance, Strand Life Sciences is poised to expand its reach and impact, continuing to lead the way in genomic innovation.
A Commitment to Ethics and Privacy
Strand Life Sciences is dedicated to upholding the highest standards of privacy and ethical practice.
Their rigorous approach ensures that genetic information is handled securely and confidentially, maintaining trust with their clients and stakeholders.
